A multi-centre, double-blind, placebo controlled, parallel group, proof of concept study to evaluate the efficacy, safety and tolerability of KRP203 in subjects with moderately active refractory ulcerative colitis.
Phase of Trial: Phase II
Latest Information Update: 24 May 2016
At a glance
- Drugs KRP 203 (Primary)
- Indications Ulcerative colitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis
- 07 Jun 2017 Biomarkers information updated
- 24 May 2016 Interim results (n = 27) presented at the Digestive Disease Week 2016.
- 19 Jun 2011 New source added and integrated (ClinicalTrials.gov, NCT01375179).